Lexaria Bioscience (LXX.C) has provided positive results from its extended stability testing, which has reported unparalleled stability for bottled cannabidiol (CBD)-containing beverages prepared using its technology.
“I love reminding people that Lexaria’s first patent was awarded in 2016 for CBD-infused beverages and consumable liquids…Our technology was working in cannabinoid beverages years before the big cannabis companies started spending hundreds of millions of dollars trying to figure it out,” said Chris Bunka, CEO of Lexaria.
Quite the humblebrag, but is it warranted? The results generated from Lexaria’s stability testing speak for themselves. The Company’s patented DehydraTECH™ CBD nano-emulsification formulation and processing techniques are responsible for the tested beverages maintaining their CBD content one year after production. Put simply, Lexaria tested beverages formulated with it DehydraTECH™ technology to see if they were able to maintain their CBD potency over the span of a year. Outstandingly, the beverages CBD content was verified at 93.4% of the target potency. This is excellent news for doomsday preppers looking to get high in their underground bunkers during the End Times!
Additionally, DehydraTECH™-processed ready-to-drink beverages were tested for content uniformity and homogeneity of CBD distribution, demonstrating less than 1% variability in CBD potency in fractions sampled from the top, middle and bottom of the tested beverages without physical mixing or agitation. There’s nothing worse than a ‘mixed’ drink that has the audacity to separate itself, setting you up for a mouthful of vodka when you least expect it. With that personal trauma aside, tested beverages formulated with DehydraTECH™ were able to maintain their consistency through and through.
Typically, beverage containing CBD often need to be shaken prior to use and tend to degrade over time. In some cases, beverages sold only contained a fraction of the CBD listed on the product label indicating an issue with manufacturing or degradation over time. On the contrary, beverages produced using Lexaria’s formulation have practically eradicated issues of decay and consistency.
In February 2020, Lexaria prepared its DehydraTECH™ formula for Nic’s Beverages and has been subjecting samples from the commercial bottling run to real-world, long-term stability testing. The results provided an average potency of 93.4% after one year with complete uniformity and no microbial growth. Testing will continue until Lexaria’s formulation no longer remains stable, although the Company cannot know when that might be.
“I am incredibly happy with the world-class results we have experienced using DehydraTECH in our CBD beverages…The coffee flavour and aroma experience are exceptional from the moment you open the bottle and remain so one year later,” said John Goodpasture, CEO of Nic’s Beverages.
Lexaria’s DehydraTECH™ technology has been clinically proven to deliver a significantly higher fraction of CBD to consumers’ blood circulation in a shorter period of time. Additional testing has also provided evidence of significantly higher brain perfusion of DehydraTECH™ CBD, which is important for human conditions that are partially or entirely regulated by the brain or central nervous system. At this point, Lexaria’s DehydraTECH™ sounds like something out of a surreal futuristic movie. With this successful testing of DehydraTECH™ beverages, the Company is sure to turn the heads of investors and manufacturers alike. Furthermore, Lexaria’s performance in the past 3 months is a testament to the versatility of DehydraTECH™ technology in other fields like medicine.
Lexaria’s stock price opened at $5.65 and reached a high of $5.886 following the news. The stock price currently sits at $5.638.